About InVivoSIM anti-human VEGFR-2 (Ramucirumab Biosimilar) This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Ramucirumab making it ideal for research use. This Ramucirumab biosimilar reacts with human VEGFR-2 (vascular endothelial growth factor receptor 2) also known as CD309, KDR, and Flk-1. VEGFR-2 is a member of the tyrosine protein kinase family. Upon binding to its ligand VEGF, VEGFR-2 pays key roles in vascular development and permeability. VEGFR-2 is expressed on endothelial cells at high levels in adult heart, lung, kidney, brain, and skeletal muscle as well as other tissues at lower levels. Ramucirumab binds to the extracellular domain of VEGFR-2 and blocks the binding of VEGFR ligands VEGF-A, VEGF-C and VEGF-D leading to inhibition of VEGF-mediated tumor angiogenesis. InVivoSIM anti-human VEGFR-2 (Ramucirumab Biosimilar) Specifications IsotypeHuman IgG1 Recommended Isotype Control(s)RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman VEGFR2 Reported ApplicationsFunctional assays Immunohistochemistry Flow cytometry FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A RRIDAB_2894733 Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
